Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout GLP1 One Rx.

FLOW Trial Results — Kidney & CV Outcomes

FLOW Trial Results

Updated October 16, 2026 with prices and facts re-checked October 14, 2026.

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

Clinical referencePubMed-linkedUpdated October 16, 2026

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

PubMed citations

PMID 38785189

Related clinical pages

Questions readers ask

Who was studied in the FLOW trial?

FLOW enrolled adults with type 2 diabetes and chronic kidney disease. It was a kidney outcomes trial published in NEJM in 2024 (PMID 38785189) that tested once-weekly semaglutide 1.0 mg.

How much did semaglutide reduce kidney and heart events in FLOW?

Semaglutide 1.0 mg weekly produced a 24% reduction in major kidney and cardiovascular events compared with placebo over a median follow-up of 3.4 years in adults with type 2 diabetes and chronic kidney disease.

Which semaglutide dose was tested in FLOW?

FLOW tested semaglutide 1.0 mg once weekly, a type 2 diabetes dose, rather than the 2.4 mg dose used for weight management. The results apply to adults with type 2 diabetes and chronic kidney disease.